Blood test could predict vasculitis relapse, study hopes

NCT ID NCT07636655

Not yet recruiting Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study follows 120 adults with ANCA-associated vasculitis, an autoimmune disease, who are receiving rituximab therapy. Researchers will collect blood samples over time to look for immune cell changes that signal a coming relapse. The goal is to find biomarkers that help doctors tailor treatment duration and reduce unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab (a drug that depletes B-cells)
What this could lead to: If successful, this could lead to a blood test that helps doctors predict when a patient with vasculitis might relapse, allowing for shorter, safer treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not find reliable markers, and any findings will need further validation before changing patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VASCULITIS ASSOCIATED WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES

Contacts and locations

Locations

CHU de Nantes

Nantes, Loire-atlantique, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.